» Articles » PMID: 33789664

Risk Factors for Lymph Node Metastasis in Gastric Neuroendocrine Tumor: a Retrospective Study

Overview
Journal BMC Surg
Publisher Biomed Central
Specialty General Surgery
Date 2021 Apr 1
PMID 33789664
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Lymph node metastasis (LNM) plays a vital role in the determination of clinical outcomes in patients with gastric neuroendocrine tumor (G-NET). Preoperative identification of LNM is helpful for intraoperative lymphadenectomy. This study aims to investigate risk factors for LNM in patients with G-NET.

Methods: We performed a retrospective study involving 37 patients in non-LNM group and 82 patients in LNM group. Data of demographics, preoperative lab results, clinical-pathological results, surgical management, and postoperative situation were compared between groups. Significant parameters were subsequently entered into logistic regression for further analysis.

Results: Patients in LNM group exhibited older age (p = 0.011), lower preoperative albumin (ALB) (p = 0.003), higher carcinoembryonic antigen (CEA) (p = 0.020), higher International normalized ratio (p = 0.034), longer thrombin time (p = 0.018), different tumor location (p = 0.005), higher chromogranin A positive rate (p = 0.045), and higher Ki-67 expression level (p = 0.002). Logistic regression revealed ALB (p = 0.043), CEA (p = 0.032), tumor location (p = 0.013) and Ki-67 (p = 0.041) were independent risk factors for LNM in G-NET patients.

Conclusions: ALB, CEA, tumor location, and Ki-67 expression level correlate with the risk of LNM in patients with G-NET.

Citing Articles

Risk factors of positive lymph node metastasis after radical gastrectomy for gastric cancer and construction of prediction models.

Dai G, Chen M, Zhu D, Cai Y, Gao M Am J Cancer Res. 2024; 14(11):5216-5229.

PMID: 39659931 PMC: 11626280. DOI: 10.62347/PEDV7297.


CDHu40: a novel marker gene set of neuroendocrine prostate cancer.

Liu S, Nam H, Zeng Z, Deng X, Pashaei E, Zang Y Brief Bioinform. 2024; 25(6).

PMID: 39318189 PMC: 11422505. DOI: 10.1093/bib/bbae471.


The Clinicopathological Characteristics and Surgical Treatment of Gastrointestinal Neuroendocrine Neoplasm-A 10-Year Single-Center Experience.

Serafin M, Jablonska B, Senderek E, Majewska K, Mrowiec S J Clin Med. 2024; 13(16).

PMID: 39201037 PMC: 11355324. DOI: 10.3390/jcm13164892.


Different lymph node staging systems for predicting the prognosis of colorectal neuroendocrine neoplasms.

Zhang Y, Cai Y, Zhang X World J Gastrointest Oncol. 2024; 16(5):1745-1755.

PMID: 38764820 PMC: 11099446. DOI: 10.4251/wjgo.v16.i5.1745.


Preoperatively predicting the lymph node metastasis and prognosis for gastric cancer patients.

Wang D, Wang Y, Dong L, Zhang X, Du J Sci Rep. 2024; 14(1):11213.

PMID: 38755185 PMC: 11099148. DOI: 10.1038/s41598-024-61671-6.


References
1.
Liang J, Liu S . [Clinicopathological features of the primary gastric neuroendocrine neoplasms]. Zhonghua Zhong Liu Za Zhi. 2014; 36(7):522-8. View

2.
Lee H, Mounajjed T, Erickson L, Wu T . Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferative Index. Endocr Pathol. 2016; 27(3):259-67. DOI: 10.1007/s12022-016-9443-6. View

3.
Crumley A, McMillan D, McKernan M, McDonald A, Stuart R . Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 2006; 94(5):637-41. PMC: 2361199. DOI: 10.1038/sj.bjc.6602998. View

4.
Kvols L, Brendtro K . The North American Neuroendocrine Tumor Society (NANETS) guidelines: mission, goals, and process. Pancreas. 2010; 39(6):705-6. DOI: 10.1097/MPA.0b013e3181eb7451. View

5.
Corey B, Chen H . Neuroendocrine Tumors of the Stomach. Surg Clin North Am. 2017; 97(2):333-343. DOI: 10.1016/j.suc.2016.11.008. View